73,646 results match your criteria Acute Myeloid Leukemia Not Otherwise Categorized


Exploiting Protein Corona around Gold Nanoparticles Conjugated to p53 Activating Peptide to Increase the Level of Stable p53 Proteins in Cells.

Bioconjug Chem 2019 Feb 15. Epub 2019 Feb 15.

Therapeutic peptides suffer from major drawbacks such as peptide degradation in vivo due to proteolysis. Gold nanoparticles (AuNPs) are an effective carrier for therapeutic peptides that improve their stability in vivo, while also enabling non-specific adsorption of complementary proteins to enhance their effectiveness. Using p53 peptide as a model known to disrupt the intracellular MDM2-p53 protein-protein interaction which tags the endogenous p53 proteins for degradation, we conjugated p53 peptides to AuNPs (AuNP-p53) and examined the functionality of AuNP-p53 to release the endogenous p53 proteins from being tagged for degradation, thereby increasing the level of stable p53 proteins in acute myeloid leukemia 2 (AML2) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.bioconjchem.9b00032DOI Listing
February 2019

[Diagnosis and treatment of acute myeloid leukemia : The updated 2018 Onkopedia Guideline].

Internist (Berl) 2019 Feb 14. Epub 2019 Feb 14.

Medizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.

In April 2018, an updated version of the previously published guidelines on acute myeloid leukemia (AML) from 2010 and 2017 was released. A revision was necessary because of two positive aspects: First, new data and insights on risk stratification and monitoring, and second, the clinical development and approval of new agents. The modified genetic risk classification allows a more precise distinction of different diagnostic groups and consequently a better matched post-remission treatment. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00108-019-0562-2
Publisher Site
http://dx.doi.org/10.1007/s00108-019-0562-2DOI Listing
February 2019
1 Read

Breast cancer resistance protein (BCRP) gene expression in a cohort of adult Egyptian patients with acute myeloid leukemia.

Afr Health Sci 2018 Dec;18(4):958-964

Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Egypt.

Background: Acute myeloid leukemia (AML), an aggressive clonal disease, is genetically heterozygous. The prognostic role of expression of Breast Cancer Resistance Protein (BCRP) gene, which behaves as a multidrug transporter, in adult AML is ambiguous.

Objective: The objective is to assess the level of mRNA expression of BCRP gene in newly diagnosed cytogenetically normal adult Egyptian AML patients; and to clarify its potential influence and association between therapeutic responsiveness and disease free survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4314/ahs.v18i4.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354849PMC
December 2018

Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Sci Rep 2019 Feb 14;9(1):2046. Epub 2019 Feb 14.

Department of Hematology, Stem Cell Transplantation Unit, University of Health Sciences,Ankara Oncology Training and Research Hospital, Ankara, Turkey.

Post-transplant cyclophosphamide has become a promising medical option after allogeneic HSCT. In this study we aimed to evaluate the efficacy of cyclophosphamide and cyclosporine combination in acute and chronic graft-versus-host disease (GvHD) prophylaxis in acute myeloid leukemia (AML) cases scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Retrospective analysis of data from 40 cases who underwent allogeneic HSCT under GvHD prophylaxis with cyclophosphamide and cyclosporine combination between April 2016 and August 2017 was made. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-38644-1DOI Listing
February 2019

SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia.

J Exp Clin Cancer Res 2019 Feb 14;38(1):80. Epub 2019 Feb 14.

Department of Biochemistry and Molecular Biology, University of Salamanca, Edificio Departamental, Lab 122, Plaza Doctores de la Reina, S/N, P.O. 37007, Salamanca, Spain.

Background: The differentiation-based therapy for acute promyelocytic leukemia (APL) is an inspiring example for the search of novel strategies aimed at treatment of other subtypes of acute myeloid leukemia (AML). Thus, the discovery of new molecular players in cell differentiation becomes a paramount research area to achieve this goal. Here, the involvement of the protein tyrosine phosphatases SHP1 and SHP2 on leukemic cells differentiation is shown, along with the therapeutic possibilities of their targeting to enhance the differentiation induction effect of phorbol esters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1097-zDOI Listing
February 2019

Investigation of phytochemical constituents of anti-leukemic herbal drugs used by the traditional healers of Purulia, Birbhum and Bankura districts of West Bengal.

Nat Prod Res 2019 Feb 15:1-6. Epub 2019 Feb 15.

b Medicinal Chemistry and Immunology Lab (ASK-II-406) School of Chemical and Biotechnology , SASTRA Deemed to Be University , Thanjavur , Tamilnadu , India.

In the present work, 16 different plant drugs used by traditional healers from West Bengal were screened through in vitro cell line model. Herbal drugs used by traditional tribal healers in Purulia, Birbhum and Bankura districts of West Bengal were collected and screening against acute myeloid leukemia (AML) cell line (HL-60). Among 16 plant extracts, bark of Flacourtia indica (66. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14786419.2019.1566818DOI Listing
February 2019

Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.

Exp Cell Res 2019 Feb 11. Epub 2019 Feb 11.

Central Laboratory, The Union Hospital of Fujian Medical University, Fuzhou, China. Electronic address:

Relapse of minimal residual disease (MRD) is a major problem after conventional chemotherapy in patients with acute myeloid leukemia (AML). The bone marrow stroma can protect AML cells from insults of chemotherapy, partly contributing to AML relapse. Arsenic trioxide (ATO) is the main component of arsenical traditional Chinese medicines and has been widely used for the treatment of hematologic malignancies particularly acute promyelocytic leukemia over the past three decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2019.02.008DOI Listing
February 2019

Current challenges for CAR T-cell therapy of acute myeloid leukemia.

Transfusion 2019 Feb 14. Epub 2019 Feb 14.

Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, and Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15199DOI Listing
February 2019

A Case of Intramuscular Cryptococcosis Mimicking a Malignant Tumor on FDG PET/CT.

Clin Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

PET/CT, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.

Intramuscular cryptococcosis is extremely rare. In this case, a 76-year-old man with history of acute myeloid leukemia presented a painful mass in the right upper arm. FDG PET/CT demonstrated a low-density irregular-shaped mass in the triceps muscle of the right upper arm with adjacent bone erosion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002488DOI Listing
February 2019

[Disseminated tuberculosis during induction chemotherapy in acute myeloid leukemia].

Internist (Berl) 2019 Feb 14. Epub 2019 Feb 14.

Klinik für Infektiologie und Spitalhygiene, Universitätsspital Basel, Petersgraben 4, 4031, Basel, Schweiz.

A patient with acute myeloid leukemia developed disseminated tuberculosis with cerebral involvement in the early phase of induction chemotherapy before allogenic stem cell transplantation. He presented with persisting fever of unknown origin, and initially misinterpreted organ lesions in CT scans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-019-0565-zDOI Listing
February 2019

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Front Oncol 2019 29;9:16. Epub 2019 Jan 29.

Hematology and Transfusion Medicine Center, Instituto Nacional de Ciência e Tecnologia do Sangue, University of Campinas, Hemocentro-Unicamp, São Paulo, Brazil.

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell-based disorders characterized by ineffective hematopoiesis, increased genomic instability and a tendency to progress toward acute myeloid leukemia (AML). MDS and AML cells present genetic and epigenetic abnormalities and, due to the heterogeneity of these molecular alterations, the current treatment options remain unsatisfactory. Hypomethylating agents (HMA), especially azacitidine, are the mainstay of treatment for high-risk MDS patients and HMA are used in treating elderly AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361844PMC
January 2019

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.

Leukemia 2019 Feb 13. Epub 2019 Feb 13.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Acute myeloid leukemias (AML) are characterized by mutations of tumor suppressor and oncogenes, involving distinct genes in adults and children. While certain mutations have been associated with the increased risk of AML relapse, the genomic landscape of primary chemotherapy-resistant AML is not well defined. As part of the TARGET initiative, we performed whole-genome DNA and transcriptome RNA and miRNA sequencing analysis of pediatric AML with failure of induction chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0402-3DOI Listing
February 2019

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.

Blood Adv 2019 Feb;3(4):508-518

Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.

Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for standard induction chemotherapy. Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m daily for 7 days in a 28-day cycle. Read More

View Article

Download full-text PDF

Source
http://www.bloodadvances.org/lookup/doi/10.1182/bloodadvance
Publisher Site
http://dx.doi.org/10.1182/bloodadvances.2018027409DOI Listing
February 2019
1 Read

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.

Int J Mol Sci 2019 Feb 12;20(3). Epub 2019 Feb 12.

Institute of Pathology, Ludwig-Maximilians University, 80539 Munich, Germany.

The development of leukemia is a step-wise process that is associated with molecular diversification and clonal selection of neoplastic stem cells. Depending on the number and combinations of lesions, one or more sub-clones expand/s after a variable latency period. Initial stages may develop early in life or later in adulthood and include premalignant (indolent) stages and the malignant phase, defined by an acute leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20030789DOI Listing
February 2019
2 Reads

Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia.

J Clin Med 2019 Feb 12;8(2). Epub 2019 Feb 12.

Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.

The modest successes of targeted therapies along with the curative effects of allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute myeloid leukemia (AML) stimulate the development of new immunotherapies. One of the promising methods of immunotherapy is the activation of immune response by the targeting of negative control checkpoints. The two best-known inhibitory immune checkpoints are cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the programmed cell death protein 1 receptor (PD-1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8020236DOI Listing
February 2019

CBX7 Induces Self-Renewal of Human Normal and Malignant Hematopoietic Stem and Progenitor Cells by Canonical and Non-canonical Interactions.

Cell Rep 2019 Feb;26(7):1906-1918.e8

European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address:

In this study, we demonstrate that, among all five CBX Polycomb proteins, only CBX7 possesses the ability to control self-renewal of human hematopoietic stem and progenitor cells (HSPCs). Xenotransplantation of CBX7-overexpressing HSPCs resulted in increased multi-lineage long-term engraftment and myelopoiesis. Gene expression and chromatin analyses revealed perturbations in genes involved in differentiation, DNA and chromatin maintenance, and cell cycle control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.01.050DOI Listing
February 2019

Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.

Ann Hematol 2019 Feb 13. Epub 2019 Feb 13.

Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030-4009, USA.

t(8;16)(p11.2;p13.3)/KAT6A-CREBBP is a rare recurrent cytogenetic abnormality associated with acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03637-7DOI Listing
February 2019

Different prognostic effects of core-binding factor positive AML with Korean AML registry data.

Ann Hematol 2019 Feb 13. Epub 2019 Feb 13.

Division of Hematology, Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, Republic of Korea.

Core-binding factor acute myeloid leukemia (CBF-AML) data in Asian countries has been rarely reported. We analyzed 392 patients with CBF-AML [281 with t(8;21), 111 with inv.(16)/t(16;16)] among data from 3041 patients with AML from the Korean AML Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03624-yDOI Listing
February 2019

Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.

Am J Cancer Res 2019 1;9(1):94-107. Epub 2019 Jan 1.

Department of Biological Sciences, Sungkyunkwan University Suwon 16419, Republic of Korea.

Covalent conjugations of the SUMO-1 moiety on a target protein play important roles in the regulation of cellular protein function. SUMO-conjugation of PML is a regulatory step for PML nuclear body (PML-NB) formation, and HIPK2 is SUMO-conjugated and recruited into the PML-NBs. Although HIPK2 mutations (R861W and N951I) were found in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients, little is known about the underlying mechanisms by which HIPK2 mutations are associated with the pathogenesis of leukemia. Read More

View Article

Download full-text PDF

Source
January 2019

Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia.

Sci Rep 2019 Feb 12;9(1):1875. Epub 2019 Feb 12.

Department of Pediatric Oncology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.

The FGF receptor signaling pathway is recurrently involved in the leukemogenic processes. Oncogenic fusions of FGFR1 with various fusion partners were described in myeloid proliferative neoplasms, and overexpression and mutations of FGFR3 are common in multiple myeloma. In addition, fibroblast growth factors are abundant in the bone marrow, and they were shown to enhance the survival of acute myeloid leukemia cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38169-zDOI Listing
February 2019

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Blood 2019 Feb 12. Epub 2019 Feb 12.

Division of Molecular Hematology, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany;

In acute myeloid leukemia (AML), acquired genetic aberrations carry prognostic implications and guide therapeutic decisions. Clinical algorithms have been improved by the incorporation of novel aberrations. Here, we report the presence and functional characterization of mutations in the transcription factor NFE2 in AML patients and in a patient with myelosarcoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-875047DOI Listing
February 2019

A semi-automated whole exome sequencing workflow leads to increased diagnostic yield and identification of novel candidate variants.

Cold Spring Harb Mol Case Stud 2019 Feb 12. Epub 2019 Feb 12.

Children's Hospital Los Angeles;

Background: Advancing the clinical utility of whole exome sequencing (WES) for patients with suspected genetic disorders is largely driven by bioinformatics approaches that streamline data processing and analysis.

Methods: Herein, we describe our experience with implementing a semi-automated and phenotype-driven WES diagnostic workflow, incorporating both the DRAGEN pipeline and the Exomiser variant prioritization tool, at an academic children's hospital with an ethnically diverse pediatric patient population.

Results: We achieved a 41% molecular diagnostic rate for 66 duo-, quad- or trio- WES cases, and 28% for 40 singleton-WES cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/mcs.a003756DOI Listing
February 2019

Exosomes in the serum of Acute Myeloid Leukemia patients induce dendritic cell tolerance: Implications for immunotherapy.

Vaccine 2019 Feb 9. Epub 2019 Feb 9.

Hematology and Transfusion Medicine Center, University of Campinas, Campinas, Brazil.

Exosomes may represent an interesting antigenic pulse for new forms of anti-tumor immunotherapy. We evaluated exosomes from serum of patients with acute myeloid leukemia (AML) as an antigenic source for dendritic cells (DC) and the effects upon antitumor cytotoxicity, assessed by the percentage of specific lysis of K562 leukemic cells in co-cultures. Surprisingly, incubation of exosomes with DCs decreased lysis of K562, which may correspond to a mechanism of tumor evasion in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2019.01.079DOI Listing
February 2019

Long-term risk of hospitalization among five-year survivors of childhood leukemia in the Nordic countries.

J Natl Cancer Inst 2019 Feb 11. Epub 2019 Feb 11.

Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.

Background: Adverse effects from childhood leukemia treatment may persist or present years after cure from cancer. We provide a comprehensive evaluation of subsequent hospitalization in five-year survivors of childhood acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).

Methods: In the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study we identified 4,003 five-year survivors diagnosed with childhood leukemia 1970-2008 in Denmark, Sweden, Iceland, and Finland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz016DOI Listing
February 2019
1 Read

Modeling cell proliferation in human acute myeloid leukemia xenografts.

Bioinformatics 2019 Feb 7. Epub 2019 Feb 7.

Department of Informatics, Systems and Communication, University of Milano-Bicocca, Milan, Italy.

Motivation: Acute myeloid leukemia is one of the most common hematological malignancies, characterized by high relapse and mortality rates. The inherent intra-tumor heterogeneity in acute myeloid leukemia is thought to play an important role in disease recurrence and resistance to chemotherapy. Although experimental protocols for cell proliferation studies are well established and widespread, they are not easily applicable to in vivo contexts, and the analysis of related time-series data is often complex to achieve. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btz063DOI Listing
February 2019
1 Read

Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.

Am J Health Syst Pharm 2019 Feb;76(5):268-274

Department of Pharmaceutical Care, University of Iowa Hospitals & Clinics, Iowa City, IA.

Purpose: This article reviews the pharmacology, efficacy, safety, cost, and future directions of midostaurin for the treatment of acute myeloid leukemia (AML), aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell leukemia, collectively known as advanced systemic mastocytosis (SM).

Summary: Midostaurin was approved by the U.S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajhp/zxy050DOI Listing
February 2019
1 Read

Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.

Ann Hematol 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China.

Donor lymphocyte infusion (DLI) might be used prophylactically to reduce relapse after allogeneic hematopoietic stem cell transplantation for very high-risk leukemia/lymphoma without effective targeted therapy. To compare the safety and efficacy of prophylactic DLI for prevention of relapse after allogeneic peripheral blood stem cell transplantation from haploidentical donors (HID-SCT) and matched-sibling donors (MSD-SCT) in patients with very high-risk acute myeloid leukemia (AML), we performed a retrospective analysis in a cohort of 21 HID-SCT and 13 MSD-SCT recipients, displaying similar baseline characteristics except for donor's gender distribution. Grade 2-4 acute graft-versus-host disease (GVHD) at 100-day post-DLI was higher in HID-SCT group than that in MSD-SCT group (59. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03636-8DOI Listing
February 2019
1 Read

Invasive fungal infection in febrile patients with hematologic malignancies undergoing chemotherapy in Iran.

Endocr Metab Immune Disord Drug Targets 2019 Feb 11. Epub 2019 Feb 11.

Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan. Iran.

Background: Patients with hematological malignancies undergoing cytotoxic chemotherapy are susceptible to develop invasive fungal infections particularly Aspergillus and Candida spp.. Early detection of these infections is required to start immediate antifungal therapy and increase survival of these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871530319666190211163245DOI Listing
February 2019

miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis.

Int J Biol Sci 2019 1;15(3):579-586. Epub 2019 Jan 1.

Department of Hepatobiliary and Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, PR China.

Daunorubicin (Dnr) is at the forefront of acute myeloid leukemia (AML) therapy, but drug resistance poses a major threat to treatment success. MicroRNA (miR)-9 has been shown to have a pivotal role in AML development. However, little is known about the role of miR-9 in Dnr resistance in AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijbs.29775DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367593PMC
January 2019
1 Read

A Pilot Study of Aberrant CpG Island Hypermethylation of in Acute Myeloloid Leukemia.

Int J Med Sci 2019 1;16(2):324-330. Epub 2019 Jan 1.

Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, 110001, China.

Epigenetic silencing of tumor suppressor genes plays important role in acute myeloid leukemia (AML). Recently, SPRED1, a negative regulator of the RAS MAPK pathway, is identified as a tumour suppressor downregulated in AML. However, little is known regarding its underlying dysregulation in AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijms.27757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367533PMC
January 2019

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity towards Resistance-conferring Mutations.

J Med Chem 2019 Feb 11. Epub 2019 Feb 11.

The use of covalent irreversible binding inhibitors is an established concept for drug development. Usually the discovery of new irreversible kinase inhibitors occurs serendipitously showing that efficient rational approaches for the rapid discovery of new drugs are needed. Herein, we report a virtual screening strategy that led to the discovery of irreversible inhibitors of the FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.8b01714DOI Listing
February 2019
1 Read

IL1RL1 is dynamically expressed on Cbfb-MYH11 leukemia stem cells and promotes cell survival.

Sci Rep 2019 Feb 11;9(1):1729. Epub 2019 Feb 11.

Department of Biochemistry and Molecular Biology, and Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States.

Acute myeloid leukemia (AML) is often characterized by the presence of specific, recurrent chromosomal abnormalities. One of the most common aberrations, inversion of chromosome 16 [inv(16)], generates the fusion oncogene CBFB-MYH11. Previously, we used a mouse knock-in model to show that Cbfb-MYH11 induces changes in gene expression and results in the accumulation of abnormal myeloid cells, a subset of which are enriched for leukemia stem cell (LSC) activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38408-3DOI Listing
February 2019
2 Reads

Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Curr Treat Options Oncol 2019 Feb 11;20(2):15. Epub 2019 Feb 11.

Department of Pathology, University of Chicago, Chicago, IL, USA.

Opinion Statement: Acute myeloid leukemia (AML) patients with a complex karyotype (CK-AML) show at least 3 unrelated clonal cytogenetic abnormalities with notoriously poor outcome. Such cases fall into either AML with myelodysplasia-related changes or therapy-related AML in the current World Health Organization classification of AML. Allogeneic stem cell transplantation is one of the only treatment modalities that can provide a long-term survival benefit and is recommended as a consolidative treatment in patients who are able to achieve complete remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0612-yDOI Listing
February 2019
1 Read

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.

Cancer Med 2019 Feb 10. Epub 2019 Feb 10.

Laboratory of Hematology, CHU Lille, Lille, France.

CD9 is a cell surface protein and belongs to the tetraspanin family. Its role in carcinomagenesis has been widely studied in solid tumors but remains controversial, depending on the cancer type. Although CD9 seems to be associated with unfavorable outcome and disease progression in acute lymphoblastic leukemia (ALL), this marker has not yet been studied in acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2007DOI Listing
February 2019
1 Read

[Expression and Clinical Significance of STAT3 Genes in Patients with Acute Myeloid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):45-51

The Affiliated Hospital of Zunyi Medical College/The Children's Hospital of Guizhou Province , Zunyi 563003, Guizhou Province, China.E-mial:

Objective: To investigate the expression of STAT3 gene in patients with acute myeloid leukemia and its correlation with clinical characteristics.

Methods: The real-time quantitative RT-PCR was used to detect the level of STAT3 mRNA in bone marrow samples from 38 newly diagnosed patients with acute myeloid leukemia(AML), and its relevance with clinical characteristics and prognosis were statistically analyzed. Western blot was employed to detect the STAT3 protein level in AML patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.008DOI Listing
February 2019
1 Read

[Clinical Analysis of 24 Acute myeloid Leukemia Patients Aged -over 80 Years].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):33-38

Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038,

Objective: To investigate the clinical features of acute myeloid leukemia patients aged over 80 years.

Methods: The clinical data from 24 cases of acute myeloid leukemia (non-M3) aged over 80 years were analyzed retrospectively. Clinical characteristics, therapeutic efficacy and overall survival rate of the patients received low dose chemotherapy and/or decitabine were compared with that received only supportive care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.006DOI Listing
February 2019
1 Read

[Expression of Transcription Factor SOX4 in Acute Myeloid Leukemia and Its Clinical Significance].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):20-24

Center of Blood Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China.E-mail:

Objective: To study the expression of SOX4 gene in patients with acute myeloid leukemia (AML) and its correlation with clinical features and prognosis, and to explore the role of this gene in acute myeloid leukemia.

Methods: The real-time guantitative PCR was used to detect the expression level of SOX4 gene in bone marrow of 96 patients with newby diagmsed AML, and the features and prognosis was analyzed.

Results: The level of SOX4 expression in the 96 AML patients was significantly higher than that in healthy controls (P<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.004DOI Listing
February 2019
2 Reads

[Mechanism of Paris Forrestii (Takht.) H. Li-Suppressing the Proliferation of Acute Myeloid Leukemia Cell Lines].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):7-13

Department of Hematology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu Province,China.E-mail:

Objective: To investigate the mechanism of Paris forrestii (Takht.) H. Li (PCT3)-suppressing the proliferation of HL-60, K562, KG-1 and HT-93 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.002DOI Listing
February 2019
1 Read

FLT3, a prognostic biomarker for acute myeloid leukemia (AML): Quantitative monitoring with a simple anti-FLT3 interaction and flow cytometric method.

J Clin Lab Anal 2019 Feb 8:e22859. Epub 2019 Feb 8.

Center for Research and Development of Natural Products for Health, Chiang Mai University, Chiang Mai, Thailand.

Background: Overexpression of fms-like tyrosine kinase 3 (FLT3) protein in leukemia is highly related to poor prognosis and reduced survival rate in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. Simple but efficient quantification of FLT3 protein levels on the leukemic cell surface using flow cytometry had been developed for rapid determination of FLT3 on intact cell surface.

Methods: Quantitation protocol for FLT3 biomarker in clinical samples was developed and validated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcla.22859DOI Listing
February 2019
2 Reads

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.

Leukemia 2019 Feb 8. Epub 2019 Feb 8.

The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Complex karyotype (CK) with ≥ 3 abnormalities is detected in 10-12% of patients with acute myeloid leukemia (AML) and associated with poor prognosis. The most common unbalanced abnormalities found in CK result in loss of material from the 5q, 7q, and/or 17p chromosome arms. The presence of 5q, 7q, and/or 17p abnormalities denotes typical CK and their absence denotes atypical CK. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-019-0390-3
Publisher Site
http://dx.doi.org/10.1038/s41375-019-0390-3DOI Listing
February 2019
3 Reads

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).

J Clin Med 2019 Feb 6;8(2). Epub 2019 Feb 6.

Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany.

Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2077-0383/8/2/200
Publisher Site
http://dx.doi.org/10.3390/jcm8020200DOI Listing
February 2019
2 Reads

Intracardiac mass in chronic myeloid leukemia.

Echocardiography 2019 Feb 8. Epub 2019 Feb 8.

Department of Cardiology, Sri Jayadeva Institute of Cardiovascular Sciences & Research, Bangalore, India.

Chronic myeloid leukaemia (CML) is a neoplastic disorder of myeloid cell lines and is a less aggressive disease compared to acute myeloid leukemia (AML). Although cardiovascular complications are not uncommon, intracardiac thrombosis in CML is rarely reported. Herein, we report a case of CML presenting with an intracardiac thrombus attached to the posterior mitral leaflet, and subsequently resulting in peripheral embolization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/echo.14279DOI Listing
February 2019
1 Read

Identifying Leukemia-Associated Immunophenotype-based Individualized Minimal Residual Disease in Acute Myeloid Leukemia and its Prognostic Significance.

Am J Hematol 2019 Feb 7. Epub 2019 Feb 7.

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, 197 Rui Jin Road II, Shanghai, China.

Based on the leukemia-associated immunophenotypes (LAIPs), minimal residual disease (MRD) related to the outcome can be detected by multiparameter flow cytometry in acute myeloid leukemia (AML) patients. Although 0.1% was commonly used as a cutoff value, measurable MRD or MRD level below 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25431DOI Listing
February 2019
1 Read
3.798 Impact Factor

Pattern of Dermatological Disease Encountered in a Hematology Ward: A Retrospective Analysis of Dermatology Consultation in a Hematology Ward in a Tertiary Care Center in Saudi Arabia.

Dermatol Res Pract 2019 13;2019:9891270. Epub 2019 Jan 13.

Intermediate Care Unit, King Abdulaziz Medical City (KAMC), National Guard Health Affairs (NGHA), Riyadh, Saudi Arabia.

Skin manifestations are common in hematology ward patients and can result from infection, malignancy, or chemotherapy. The purpose of this study was to identify the most common dermatological problems encountered in the adult hematology ward at King Abdullah Specialist Children Hospital (KASCH). This was retrospective chart review of 78 dermatology consultations based on electronic health records for all inpatients in hematology wards at KASCH between January 2016 and December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/9891270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348816PMC
January 2019
1 Read

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Hématologie clinique, Hôpital Saint-Louis, Paris, France;

High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel subcutaneous hypomethylating agent, which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safety of guadecitabine in high-risk myelodysplastic syndrome and low blast count acute myeloid leukemia patients refractory or relapsing after azacitidine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207118DOI Listing
February 2019
1 Read

Sequential therapy for patients with primary refractory acute myeloid leukemia - historical prospective analysis of the German and Israeli experience.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Department I of Internal Medicine, University of Cologne, Germany.

Primary refractory acute myeloid leukemia is associated with a dismal prognosis. The fludarabine, amsacrine, and cytarabine-reduced-intensity conditioning protocol (total body irradiation or treosulfan-based) has been described to be an effective approach in patients with refractory leukemia undergoing allogeneic hematopoietic cell transplantation . A modified protocol (without amsacrine) has been also used recently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.203869DOI Listing
February 2019
1 Read

Ectopic ATP synthase β subunit proteins on human leukemia cell surface interact with platelets by binding glycoprotein IIb.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Lab of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou, China;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.216390DOI Listing
February 2019
1 Read

Plasma fibrinogen levels correlate with prognosis and treatment outcome in patients with non-M3 acute myeloid leukemia.

Leuk Lymphoma 2019 Feb 8:1-9. Epub 2019 Feb 8.

a Department of Hematology, Wenzhou Key Laboratory of Hematology , the First Affiliated Hospital of Wenzhou Medical University , Wenzhou , China.

To assess plasma fibrinogen levels as a biomarker to predict the prognosis and treatment outcome in acute myeloid leukemia (AML), a retrospective study of 215 patients with AML excluding M3 was conducted in a single center. Patients were divided into low and high group according to the cutoff value of 3.775 g/L obtained by analyzing the receiver operating characteristic (ROC) curve of fibrinogen at diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1535116DOI Listing
February 2019
1 Read

Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.

Leuk Lymphoma 2019 Feb 7:1-9. Epub 2019 Feb 7.

a Division of Oncology , The Children's Hospital of Philadelphia , Philadelphia , PA , USA.

Equal access to clinical trial enrollment is important to ensure that findings are generalizable to the broader population. This study aimed to evaluate disparities in enrollment on pediatric oncology clinical trials. We assessed the relationship between patient characteristics and enrollment on COG trial AAML1031 in a cohort of pediatric patients with AML in the Pediatric Health Information System. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1574002DOI Listing
February 2019
1 Read